20(R)-Rg3 treatment not only attenuated fasting blood glucose (FBG) levels and advanced glycation end products (AGEs) levels but also improved insulin (INS) levels, blood lipids, oxidative stress, and renal function by regulating MAPKs and NF-κB signal pathways in diabetic nephropathy mice [134]. This evidence concerns the gene INS and diabetic kidney disease.